Vir Biotechnology, Inc. progresses HDV treatment with promising ECLIPSE program results. Click here to find out why VIR stock ...

The global Burn Care Market is projected to be valued at USD 2.79 billion in 2024 and reach US$ 4.23 billion by 2030, growing ...

Unlike traditional fat burners that rely on caffeine or complicated routines, Flash Burn offers a simple ... is not a drug and does not mimic GLP-1 medications. Pricing starts at $69 for a ...

So, the natural question for Mereo BioPharma Group (NASDAQ:MREO) shareholders is whether they should be concerned by its rate of cash burn. In this report, we will consider the co ...

Capricor's lead asset, deramiocel, targets DMD-related cardiomyopathy and faces key FDA milestones. Find out why CAPR stock ...

But the harsh reality is that very many loss making companies burn through all their cash and go bankrupt. So should CollPlant Biotechnologies (NASDAQ:CLGN) shareholders be worried about its cash burn ...

Shares of biotechnology company Prime Medicine, Inc. (PRME) fell 18% on Monday afternoon after the company announced a ...

Unlike traditional fat burners that rely on caffeine or complicated routines, Flash Burn offers a simple ... alternative”, though it is not a drug and does not mimic GLP-1 medications. Pricing starts ...

T he cost of prescription drugs in the U.S. has long outpaced that of peer nations, a dynamic driven by a combination of ...

Having said that, unprofitable companies are risky because they could potentially burn through all their cash and become distressed. So should Spanish Mountain Gold (CVE:SPA) shareholders be worried ...

Unity Biotechnology and Mammoth Biosciences are ... from its phase 2b Aspire trial that weighed its investigational eye treatment UBX1325 against Regeneron’s blockbuster Eylea in patients ...

Allan Reine, the company's chief financial officer, has been named CEO and will become a member of the board. Jeff Marrazzo, another director, has been named executive chair. Prime's shares fell 8.2% ...